Cargando…

Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report

Mutations in nuclear-encoded genes that are involved in mitochondrial DNA replication and maintenance (e.g., POLG) have been associated with chronic progressive external ophthalmoplegia (CPEO) phenotype. These nuclear genome mutations may lead to multiple mitochondrial DNA deletions or mitochondrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang-Orsini, Melanie, Gonzalez-Perez, Paloma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957867/
https://www.ncbi.nlm.nih.gov/pubmed/35350396
http://dx.doi.org/10.3389/fneur.2022.846110
_version_ 1784676824508268544
author Lang-Orsini, Melanie
Gonzalez-Perez, Paloma
author_facet Lang-Orsini, Melanie
Gonzalez-Perez, Paloma
author_sort Lang-Orsini, Melanie
collection PubMed
description Mutations in nuclear-encoded genes that are involved in mitochondrial DNA replication and maintenance (e.g., POLG) have been associated with chronic progressive external ophthalmoplegia (CPEO) phenotype. These nuclear genome mutations may lead to multiple mitochondrial DNA deletions or mitochondrial DNA depletion. On the other hand, primary genetic defects of mitochondrial DNA (such as single large-scale deletion or point mutations) have also been associated with the CPEO phenotype. Chronic progressive external ophthalmoplegia (CPEO) may be a manifestation of specific syndromes that, when clinically recognized, prompt clinicians to investigate specific genetic defects. Thus, CPEO, as part of Kearns Sayre syndrome, suggests the presence of a large-scale deletion of mitochondrial DNA. However, in pure CPEO or CPEO plus phenotypes, it is more difficult to know whether causative genetic defects affect the nuclear or mitochondrial DNA. Here, we present a patient with a long-standing history of CPEO plus phenotype, in whom the sequencing of mitochondrial DNA from skeletal muscle was normal, and no other genetic defect was suspected at first. At the time of our evaluation, the presence of polyneuropathy and neuropathic pain prompted us to investigate nuclear genetic defects and, specifically, mutations in the POLG gene. Thus, the sequencing of the POLG gene revealed p.Thr251Ile and p.Pro587Leu mutations in one allele, and p.Ala467Thr mutation in another allele. Although one would expect that mutations in POLG lead to multiple mitochondrial DNA deletions or depletion (loss of copies), the absence of mitochondrial DNA abnormalities in tissue may be explained by heteroplasmy, a lack or no significant involvement of biopsied tissue, or a sampling bias. So, the absence of secondary mitochondrial DNA alterations should not discourage clinicians from further investigating mutations in nuclear-encoded genes. Lastly, mitochondrial point mutations and single mitochondrial DNA deletions very rarely cause CPEO associated with polyneuropathy and neuropathic pain, and POLG-related disease should be considered in this scenario, instead.
format Online
Article
Text
id pubmed-8957867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89578672022-03-28 Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report Lang-Orsini, Melanie Gonzalez-Perez, Paloma Front Neurol Neurology Mutations in nuclear-encoded genes that are involved in mitochondrial DNA replication and maintenance (e.g., POLG) have been associated with chronic progressive external ophthalmoplegia (CPEO) phenotype. These nuclear genome mutations may lead to multiple mitochondrial DNA deletions or mitochondrial DNA depletion. On the other hand, primary genetic defects of mitochondrial DNA (such as single large-scale deletion or point mutations) have also been associated with the CPEO phenotype. Chronic progressive external ophthalmoplegia (CPEO) may be a manifestation of specific syndromes that, when clinically recognized, prompt clinicians to investigate specific genetic defects. Thus, CPEO, as part of Kearns Sayre syndrome, suggests the presence of a large-scale deletion of mitochondrial DNA. However, in pure CPEO or CPEO plus phenotypes, it is more difficult to know whether causative genetic defects affect the nuclear or mitochondrial DNA. Here, we present a patient with a long-standing history of CPEO plus phenotype, in whom the sequencing of mitochondrial DNA from skeletal muscle was normal, and no other genetic defect was suspected at first. At the time of our evaluation, the presence of polyneuropathy and neuropathic pain prompted us to investigate nuclear genetic defects and, specifically, mutations in the POLG gene. Thus, the sequencing of the POLG gene revealed p.Thr251Ile and p.Pro587Leu mutations in one allele, and p.Ala467Thr mutation in another allele. Although one would expect that mutations in POLG lead to multiple mitochondrial DNA deletions or depletion (loss of copies), the absence of mitochondrial DNA abnormalities in tissue may be explained by heteroplasmy, a lack or no significant involvement of biopsied tissue, or a sampling bias. So, the absence of secondary mitochondrial DNA alterations should not discourage clinicians from further investigating mutations in nuclear-encoded genes. Lastly, mitochondrial point mutations and single mitochondrial DNA deletions very rarely cause CPEO associated with polyneuropathy and neuropathic pain, and POLG-related disease should be considered in this scenario, instead. Frontiers Media S.A. 2022-03-08 /pmc/articles/PMC8957867/ /pubmed/35350396 http://dx.doi.org/10.3389/fneur.2022.846110 Text en Copyright © 2022 Lang-Orsini and Gonzalez-Perez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Lang-Orsini, Melanie
Gonzalez-Perez, Paloma
Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title_full Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title_fullStr Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title_full_unstemmed Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title_short Neuropathic Pain as Main Manifestation of POLG-Related Disease: A Case Report
title_sort neuropathic pain as main manifestation of polg-related disease: a case report
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957867/
https://www.ncbi.nlm.nih.gov/pubmed/35350396
http://dx.doi.org/10.3389/fneur.2022.846110
work_keys_str_mv AT langorsinimelanie neuropathicpainasmainmanifestationofpolgrelateddiseaseacasereport
AT gonzalezperezpaloma neuropathicpainasmainmanifestationofpolgrelateddiseaseacasereport